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Recently, CD133 was detected in
subsets of neoplastic cells in human
primary cutaneous squamous cell carci-
nomas (SCCs) with TIC characteristics
(Patel et al., 2012), which raises two
important questions regarding the signi-
ficance of CD133 in non-melanoma
skin cancer. First, do CD133þ SCC-
initiating cells descend from trans-
formed CD133þ keratinocyte hair
follicle stem cells? Second, are there
common regulatory mechanisms that
underlie the regenerative and self-
renewal capacities of normal and neo-
plastic CD133þ keratinocytes? Recent
studies using genetic pulse–chase label-
ing approaches to genetically tag epider-
mal stem cells have helped to address the
first question by demonstrating that bulge
stem cells are susceptible to oncogenic
Ras and serve as a cell of origin for SCCs,
whereas transit cell populations are
unable to initiate SCCs under the same
conditions (reviewed in Thieu et al.,
2012). As for the latter question, the
further characterization of the CD133þ
bulge stem cell subset may be critical to
our understanding of the cellular basis for
SCC initiation and progression.
In summary, Charruyer and collea-
gues (2012) have presented significant
advances to the field of cutaneous kera-
tinocyte stem cells, including a pair of
new selectable markers that represent a
subset of a6þCD34þ label-retaining
cells and a new in vivo limiting dilu-
tion assay for keratinocyte stem cells
with long-term repopulating ability. This
work has important implications for
keratinocyte stem cell identification,
culture, and assay, as well as for identi-
fying the target cells in the pathogenesis
of non-melanoma skin cancer.
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Out of the Skin of Babes: Measuring
the Full Impact of Atopic Dermatitis
in Infants and Young Children
Amy S. Paller1 and Mary-Margaret Chren2
Valid psychometric instruments should be culturally adapted and refined with use.
Neri et al. present an excellent example of this process for the Childhood Atopic
Dermatitis Impact Scale. The work emphasizes that psychometric measurement
continues to develop and reminds us that optimal care of children with atopic
dermatitis requires considering its multidimensional effects on both the children
and their families.
Journal of Investigative Dermatology (2012) 132, 2494–2496; doi:10.1038/jid.2012.354
Atopic dermatitis (AD) manifests initially
during the preschool years in B90% of
affected individuals and has been shown
to have a significant impact on the
quality of life (QOL) of patients and their
families (Chamlin and Chren, 2010).
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Pruritus in infants and young children has
been associated with increased
irritability, crying, clingy behavior,
excessive dependency, and fearfulness.
Young children with AD experience diffi-
culty in falling asleep, restless sleep, and
frequent night wakening, which translate
into daytime sleepiness, restlessness, and
disruptive behavior that can be mistaken
for learning disabilities and behavioral
abnormalities. The physical, emotional,
social, and financial impact of AD on the
family of a young child is also signi-
ficant. In 30% of families of young
children with AD, the child’s sleep dis-
turbance is managed by co-sleeping
(bed or room sharing with the parent)
(Chamlin et al., 2005b), which leads to
parental sleep deprivation, often because
the parents stroke the child’s skin or hold
the child’s hands throughout the night to
prevent them from scratching. The total
hours of lost sleep for parents average
upto 1–2 hours per night, in addition to
the 2–3 hours spent daily in caring for
their child (Su et al., 1997). To help cope
with the needs of the child, parents often
make financially stressful changes in
their lifestyle and home environ-
ment. Parents often experience sadness,
worry, and self-blame (especially if they
also have atopy) because of their child’s
AD. These emotions are exacerbated
by the negative reactions and unsoli-
cited advice from friends, relatives, and
strangers. In their effort to avoid poten-
tial environmental triggers, minimize
conflict, and care for their young chil-
dren, AD parents of children often stay at
home, which may increase their feelings
of social isolation.
New interventions for treating AD and
comparative effectiveness trials are des-
perately needed, including in affected
young children. Assessment of the phy-
sical signs of AD is routine in these trials,
using instruments such as SCORAD
(Severity Scoring of Atopic Dermatitis)
and EASI (Eczema Area and Severity
Index). In the past decade, however,
the impact of AD on QOL has been
stressed, and instruments that measure
QOL have increasingly been used (Rehal
and Armstrong, 2011). The CDLQI
(Children’s Dermatology Life Quality
Index) was developed and validated in
1995 as a variation of the DLQI to
measure QOL in children aged 4 years
and above, and it has been the most
commonly used QOL scale for pediatric
studies of skin disease. Its 10 questions
address itching and sleep-loss issues, but
also psychosocial effects on school per-
formance, friendships, bullying, enjoy-
ment of vacation, and participation in
sports (Lewis-Jones and Finlay, 1995).
For quantifying the effect of skin
disorders on infants (0–4 years of age),
the IDQOL (Infants’ Dermatitis Quality
of Life Index) was developed in 2001
(Lewis-Jones et al., 2001). As in the
CDLQI, the IDLQI includes 10 ques-
tions that probe issues related to itch-
ing, sleep, play and family activities,
mealtimes, mood, bathing and dressing,
and parental assessment of disease
severity. Additional QOL instruments
specifically examine the effect of AD on
the family (dermatitis family impact (DFI);
Parent’s Index of Quality of Life in Atopic
Dermatitis (PIQoL-AD)); and Parents of
Children with Atopic Dermatitis (PQoL-
AD) (Rehal and Armstrong, 2011). None
of these scales individually, however,
measures the multidimensional effects of
AD on QOL in both young children and
their parents.
To address this gap, Chamlin and
colleagues developed, tested, and refined
the Childhood Atopic Dermatitis Impact
Scale (CADIS) in American patients
(Chamlin et al., 2005a; Chamlin et al.,
2007). CADIS is a hypothesis-based QOL
tool to measure the effects of AD on the
lives of children younger than 6 years
and their parents. The 45-item instrument
was developed from an explicit concep-
tual framework based on substantial
qualitative input from families and
expert medical professionals; because of
this input, CADIS focuses considerably
on the emotional aspects of AD, in
addition to its symptoms and functional
and social effects.
The relative paucity of studies of
interventions in infants and young chil-
dren has limited experience in clinical
trials with CADIS, and, to our knowl-
edge, the instrument has not been pre-
viously translated and adapted for other
cultures. In addition, because it has 45
items, CADIS is more cumbersome to
use than the other pediatric QOL scales,
most of which have 10 questions.
Recently, Neri et al. (this issue, 2012)
tested the validity of CADIS outside of
the United States, and used psycho-
metric criteria to develop a shortened
version of the instrument, which they
tested for evidence of validity.
The Italian version of the CADIS
was translated using standard interna-
tional guidelines, and the investi-
gators used strict disease definitions
and valid measures of disease severity.
Scores with the Italian CADIS were
compared with those from existing,
widely accepted scales, using a priori
hypotheses about the degree of
expected correlation. In addition, the
investigators developed what they
learned from the psychometric tests.
For example, they did not simply report
the elimination of items that failed to
correlate significantly or exclusively
with ‘factors’ (i.e., hypothesized con-
cepts) that explained variance in
patients’ responses. Instead, they used
the results to infer clues about possible
cultural differences in Italian children or
Clinical Implications
 To evaluate treatment strategies for Atopic dermatitis (AD) in children,
researchers must measure validly AD’s broad effects on patients and
their families.
 Childhood Atopic Dermatitis Impact Scale (CADIS), the 45-item CADIS
tool developed in the United States to measure the quality-of-life effects
of atopic dermatitis on young children and their families has been
adapted for Italian patients, and a shortened 33-item version has
evidence of reliability and validity.
 Clinicians who care for young children with atopic dermatitis should
consider children’s symptoms and activity limitations, as well as
parents’ emotions, family and social function, and parents’ sleep.
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families compared with those from the
United States.
Despite the many strengths of Neri
et al.’s report, we might understand
more about the experiences of Italian
families with more open-ended items
that inquired about the effects of AD.
These responses would permit us to
know about effects that were not addres-
sed in the CADIS, which is important
for content validity of the Italian version.
We might also learn whether some
aspects for which the items were not
psychometrically robust (such as avoid-
ing photos or effects of childhood AD
on parents’ work) are more typical of
Americans than Italians. An intriguing
example of an aspect about which we
want more qualitative information is
that over 40% of Italian parents categor-
ized the economic costs of the condition
as ‘high’ (Table 1, in the Neri et al.
(2012) manuscript). We are not given
information to understand more about
this experience, nor how it compares
with those of American respondents in
the original development and validation
work on CADIS (most of whom had
private health insurance and reported
family incomes of 4$75,000).
The study is a good example of a
methodologically rigorous adaptation
and testing of a patient-reported instru-
ment for a different country from the
one in which it was developed. How-
ever, as the authors note, the CADIS
was designed using classical test theory
rather than approaches that use item
response theory (IRT) methods, such
as Rasch modeling. Although classical
test theory has been the conventional
approach to the development and
refinement of psychometric tools used
in clinical medicine, IRT is a next-
generation quantitative methodology
that among other attributes considers
the ‘‘difficulty’’ of each item and permits
the use of computerized adaptive testing
techniques with which the patient res-
ponds to a highly tailored set of questions
based on his or her previous answers
(McHorney, 1997). IRT methods typi-
cally result in instruments that are more
generalizable, which is a strength when
tools are used in patients from different
cultures. However, IRT testing requires
larger samples compared with those
studied in this work. In addition, it
requires measurement of concepts that
are unidimensional (i.e., single psycho-
logical attributes affect patients’ res-
ponses). As demonstrated by the CADIS,
the effects of AD on small children and
their families are multidimensional.
The growing list of instruments for
evaluation of AD has prompted the estab-
lishment of the HOME initiative (Harmo-
nizing Outcome Measures for Eczema),
which uses Delphi exercises to develop
consensus-based sets of core outcome
domains for AD for use in clinical trials
and visit documentation (Schmitt et al.,
2011). This panel has begun to assess
physician-determined clinical signs,
patient symptoms, and long-term control
of flares as core outcome domains, and
shortly it will evaluate QOL scales as
well. Although several 10-question instru-
ments have already been used in trials
that separately address the impact on
infants (Infant’s Dermatitis Quality of
Life Index), young children (CDLQI),
and parents (Dermatitis Family Impact
questionnaire), future intervention trials
for infants and children under 6 years of
age should consider the use of the CADIS
instrument as an assessment tool that
includes impact on both the child and
parents, particularly if additional simplifi-
cation of the instrument is undertaken.
In routine clinical practice, even
10-question scales are too onerous for
most practitioners. Nevertheless, the five
domains of the CADIS instrument (Child
Symptoms; Child Activity Limitations;
Parent Emotions; Family and Social
Function; and Parent Sleep) must be
broached in our discussions with
families. Focus only on the visible fea-
tures of AD, such as the erythema and
lichenification, without incorporation
into our encounter of the ‘‘vital signs’’
(Chren, 2005) of dermatologic evalu-
ation—the physical, emotional, and
functional impact of skin disease—may
lead to treatment decisions that do not
adequately address familial needs, thus
reducing compliance and worsening
clinical outcome.
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